Merck & Co has revised its annual profit and revenue forecasts upward, buoyed by robust sales of its blockbuster cancer drug Keytruda.
Merck & Co has revised its annual profit and revenue forecasts upward, buoyed by robust sales of its blockbuster cancer drug Keytruda.